EUVIMEDEUVIMED entdecken
Crossref

Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1668c ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Anti-Allergic Agents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase, and generics) and the corticosteroid mometasone furoate (Nasonex 24 HR Allergy, and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhinitis, AllergicAnti-Allergic AgentsHumansMometasone FuroateOlopatadine HydrochlorideFluticasoneAdministration, IntranasalPhthalazinesDouble-Blind MethodAndrostadienes

Stichwörter der Autor:innen

Astepro AllergyDymistaFlonase Allergy ReliefNasonexPatanaseRyaltrisadverse effectsallergic rhinitisantihistaminesazelastineazelastine/fluticasone propionatecorticosteroidsdosagedrug interactionsefficacy

Substanzen

Mometasone FuroateOlopatadine HydrochlorideAnti-Allergic AgentsFluticasonePhthalazinesAndrostadienes

Zitieren

APA

(2023). Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668c

Vancouver

Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668c

BibTeX
@article{euvimed2023,
  title = {Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1668c}
}
Kostenlos starten →